Clinical Trial Search

Primary: The Standardized Photosensitivity Range (SPR) in the Subject's Most Sensitive Eye Condition — 0.57; 1.38; 1.58; 6.80 Units on a scale

Primary: Maximum Observed Change From Pretreatment Baseline in the Standardized Photosensitivity Range (SPR) — -0.2; -4.4; -5.2; -4.8 Number of frequency steps

Primary: % Change in Frequency of Handwaving Episodes — -66.2 % change in hand waving episodes — p=<0.001

Primary: Difference in SPR During Placebo and VPA Infusions — 15.917; 14.609 standard photosensitive range (SPR) — p=0.016

Primary: Change From Baseline in the Mean Number of Daily Seizures at 1 Year. — 9 Number of Seizures — p=<0.02

Primary: To Determine if the Frequency of Premenstrual Dysphoric Disorder Differs Among Various Antiepileptic Drug Monotherapies. — 0; 0; 0; 2 Participants

Primary: Ratio of Spike-Wave Index (SWI) During First Hour of Nonrapid Eye Movement (NREM) Sleep at Week 6 — -0.02; 0.01 Log-transformed ratio — p=0.4326

Primary: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy — 81; 43; 85 Participants — p=<0.001

Primary: Sleep Latency Wakefulness After Sleep Onset (WASO) — 42.3; 57.3 minutes/night

Primary: Cognitive Assessment Scores and Developmental Impact — 83.9; 80.9; 97.3; 85.0 score on a scale — p=0.8681

Primary: Percentage of Participants With a Decrease (p<0.05) From Baseline in Threshold Value in Any 5 or More Points in Humphrey 24-2 Swedish Interactive Threshold Algorithm…

Primary: Change in Baseline Visual Evoked Potential (P100) Amplitude

Primary: Time to First Seizure — 169; 178 Days

Primary: Mean Change From Reference Value in Field Width as Measured by 30-2 SITA Fast in Field Sensitivity (Mean Deviation - MD in dB) — -0.28; -0.24; -0.14; -0.13 dB

Primary: Number of Participants With Occurrence of Seizure — 0; 1 Participants

Primary: Number of Nonepileptic Seizures (NES) — 5.0; 6.0; 3.0; 6.0 seizures — p=0.29

Primary: Proportion of Participants Who Achieve Their Assigned Step Goal - Adherence — 0.267 Proportion

Primary: Study Recruitment Rate — 3.8 participants/3 months

Primary: 50% Responder Rate — 40.5; 15.6 percentage of participants

Primary: Inter-rater Agreement of the International Federation of Clinical Neurophysiology (IFCN) Criteria (Cut-off=4) in Sensor Space and of Detection of Epileptiform Discharges…

Primary: Number of Subjects in the Safety Analysis Set With at Least 1 Treatment-emergent Adverse Event (TEAE) — 84; 14; 10; 1 Participants

Primary: Sleep Onset Latency — 22.80; 29.99 minutes

Primary: Post-Traumatic Epilepsy — 6; 8 participants

Primary: The Primary End Point for This Study is a 50% Fluoxetine-related Reduction in the Number of Seizures With Associated Oxygen Desaturations Below 90% Compared With Placebo.

Primary: 58-week Retention Rate Measured by the Number of Drop Outs Due to Adverse Events or Seizures From Day 1 of Treatment — 0.61; 0.46; 0.56 proportion of participants…

Primary: Mean Weekly Log-transformed Seizure Frequency During Weeks 1 Through 10 — 5.20; 10.77 log[seizures per week]

Primary: Functional Connectivity

Primary: Number of Subjects Who Had a Driving Simulator Crash Event — 2; 0 Participants — p=0.50

Primary: Mean AUC0-last_ss (Test vs. Reference) — 92.884; 62.76666667; 419.97; 260.3 micro/mL/hr

Primary: Percent of Participants That Experienced Clinically Meaningful Change in Lamotrigine Level — 0 percentage of participants